What Researchers Did
Researchers reported on a single insulin-dependent diabetic patient with rhino-sinuso-orbital mucormycosis who received aggressive surgical debridement, increased amphotericin B, and adjunctive hyperbaric oxygen after initial treatments failed.
What They Found
After initial treatments failed, the patient received an additional 3900 mg of amphotericin B (totaling 6800 mg) and adjunctive hyperbaric oxygen. This combined approach led to a successful outcome with no evidence of relapse after 16 months.
What This Means for Canadian Patients
For Canadian patients with severe mucormycosis that is resistant to standard treatments, adjunctive hyperbaric oxygen therapy could be considered as a potential treatment option. This approach may offer an additional strategy to improve outcomes in complex cases, particularly for those with underlying conditions like diabetes.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a single case report, the findings of this study cannot be generalized to a broader patient population.